title: [Recent Therapy of Organ-confined Testis Cancer].
abstract: BACKGROUND
  In Germany, testicular cancer accounts for about 1-2% of all malignant tumours. Although, therefore, this is a rare tumour, it assumes an exceptional position among malignant tumours in several respects. In male patients aged 20-35 years it is the most common tumour, which directly affects the family and life planning of young men, a matter of prime importance at this age. Another aspect of testicular cancer is its excellent prognosis since the introduction of platinum-based chemotherapy into the armamentarium of testicular cancer therapy. Therefore, therapeutic innovations increasingly focus on reducing the radicality of treatment, even more so since this therapy, in addition to acute toxicity, can cause severe long-term consequences up to and including secondary malignancies.
  
  
  OBJECTIVE
  This article gives an overview of the present therapeutic standard of stage I testicular cancer treatment.
  
  
  METHODS
  Selective PubMed research Results and Discussion: Besides potential implications for organ-sparing surgery, the article elucidates the benefits of a risk-adapted therapeutic approach and indications for a surveillance strategy for patients with localised testicular cancer.
authors.affiliation: Klinik für Urologie und Kinderurologie, Universitätsklinikum Ulm.
authors.forename: C
authors.initials: C
authors.lastname: Breunig
authors.affiliation: Klinik für Urologie und Kinderurologie, Universitätsklinikum Ulm.
authors.forename: F
authors.initials: F
authors.lastname: Zengerling
authors.affiliation: Klinik für Urologie und Kinderurologie, Universitätsklinikum Ulm.
authors.forename: T
authors.initials: T
authors.lastname: Schnöller
authors.affiliation: Klinik für Urologie und Kinderurologie, Universitätsklinikum Ulm.
authors.forename: M
authors.initials: M
authors.lastname: Schrader
authors.affiliation: Klinik für Urologie und Kinderurologie, Universitätsklinikum Ulm.
authors.forename: F
authors.initials: F
authors.lastname: Jentzmik
mesh_terms: D000328:Adult; D059186:Chemoradiotherapy, Adjuvant; D003131:Combined Modality Therapy; D005858:Germany; D019983:Guideline Adherence; D006801:Humans; D008297:Male; D009367:Neoplasm Staging; D009373:Neoplasms, Germ Cell and Embryonal / Q000473:pathology / Q000628:therapy*; D009919:Orchiectomy; D011379:Prognosis; D018239:Seminoma / Q000473:pathology / Q000628:therapy*; D013736:Testicular Neoplasms / Q000473:pathology / Q000628:therapy*; D013737:Testis / Q000473:pathology